CONNECT WITH US
HealthTech

HealthTech

Precision Neuroscience raises $250M for brain-computer interface work

MedTech Dive logo

Published on

Add as a preferred source on Google
Precision Neuroscience raises $250M for brain-computer interface work

The Series D round is part of a surge in investment into BCI startups and brings Precision Neuroscience’s total funding to $430 million.

Companies have various approaches to interfacing with the brain, differentiated, in part, by how invasive their technologies are. While Elon Musk’s Neuralink is developing electrodes that connect to the brain, Precision Neuroscience has created a thin, flexible BCI that sits on the organ’s surface.

Precision Neuroscience’s Layer 7 is thinner than a human hair and features 1,024 electrodes on a device the size of a postage stamp. The design allows surgeons to implant the cortical interface via a “micro-slit incision technique.” Precision Neuroscience received Food and Drug Administration clearance for 30-day use of the device last year.

The Series D round, which brings Precision Neuroscience’s total funding to $430 million, positions the company to expand its clinical program, advance Layer 7 through the next stages of FDA review and build commercialization infrastructure.

Pershing Square, the Ackman Oxman Institute and an undisclosed life sciences investment fund co-led the financing round. Investor Bill Ackman, CEO of Pershing Square and co-founder of the Ackman Oxman Institute brain research center, is a key figure in the financing.

“Neurotechnology will be central to the next generation of cures, treatments and rehabilitation,” Ackman said in a statement.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.